Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Nicox SA","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nicox\u2019s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE\u00ae In Agreement with Hikma","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Nicox SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nicox Partners with Laboratorios Grin to Bring ZERVIATE to Mexico","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Nicox SA","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","amount":"$19.2 million","upfrontCash":"Undisclosed","newsHeadline":"Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment Under ZERVIATE\u00ae Agreement","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox\u2019s Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"OcuMension Therapeutics","sponsor":"Nicox SA","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE in China","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Cetirizine

    Menu

    Cetirizine

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              OcuMension Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nicox's Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE in China

              Details:

              ZERVIATE is the first and only eye drop formulation of the antihistamine cetirizine, the active ingredient in ZYRTEC®, and is currently commercialized in the U.S. for ocular itching associated with allergic conjunctivitis.

              Lead Product(s): Cetirizine

              Therapeutic Area: Ophthalmology Product Name: Zerviate

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Nicox SA

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nicox SA

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment Under ZERVIATE® Agreement

              Details:

              ZERVIATE is the first and only topical ocular formulation of the antihistamine cetirizine and has been commercialized in the United States since March 2020 by Nicox’s exclusive U.S. licensee, Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen (Japan).

              Lead Product(s): Cetirizine

              Therapeutic Area: Ophthalmology Product Name: Zerviate

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: OcuMension Therapeutics

              Deal Size: $19.2 million Upfront Cash: Undisclosed

              Deal Type: Agreement July 05, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Lupin Ltd

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nicox Partners with Laboratorios Grin to Bring ZERVIATE to Mexico

              Details:

              Nicox will receive an undisclosed license fee and potential milestone payments linked to regulatory approval and sales, and is eligible to receive double digit royalties on net sales of ZERVIATE.

              Lead Product(s): Cetirizine

              Therapeutic Area: Ophthalmology Product Name: Zerviate

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Nicox SA

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 05, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Nicox SA

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nicox’s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma

              Details:

              Hikma will be responsible for promoting ZERVIATE to U.S. healthcare professionals working outside the eyecare specialty, with all sales continuing to be booked by Eyevance, on which Nicox will receive royalties.

              Lead Product(s): Cetirizine

              Therapeutic Area: Ophthalmology Product Name: Zerviate

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Hikma Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement February 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OcuMension Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Nicox’s Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China

              Details:

              The Phase 3 trial is evaluating the safety and efficacy of ZERVIATE , first and only topical ocular formulation of the antihistamine cetirizine, for the treatment of ocular itching associated with allergic conjunctivitis.

              Lead Product(s): Cetirizine

              Therapeutic Area: Ophthalmology Product Name: Zerviate

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              DRL Cetirizine
              Supriya Lifescience Cetirizine
              Close
              4
              Post Enquiry
              POST ENQUIRY